FAQ: BitFrontier Capital Holdings, Inc. Appoints New CEO for Strategic Turnaround

Who has been appointed as the new CEO of BitFrontier Capital Holdings, Inc.?

Dr. Jordan P. Balencic has been appointed as the new CEO of BitFrontier Capital Holdings, Inc.

What is the main goal of Dr. Balencic’s appointment?

The main goal is to lead a comprehensive turnaround strategy aimed at realigning the Company’s capital structure, business model, and shareholder value proposition.

What experience does Dr. Balencic bring to BFCH?

Dr. Balencic is a physician entrepreneur and public company advisor with over a decade of experience in the health and wellness industry, expertise in governance, strategic pivots, capital formation, and investor engagement.

What strategic actions does BFCH intend to pursue under Dr. Balencic’s leadership?

BFCH intends to pursue debt elimination, a business model pivot to consumer health innovation, corporate rebrand, capital structure optimization, governance reform, and OTCQB uplisting intent.

What sectors is BFCH targeting with its new operating strategy?

BFCH is targeting functional foods, nootropic beverages and supplements, food and beverage manufacturing infrastructure, digital health and wearable technologies, AI-driven cognitive assessment tools and coaching, and early-stage health-tech acquisitions and brand incubation.

When does BFCH intend to pursue OTCQB qualification?

BFCH intends to pursue OTCQB qualification in 2026.

What are the expected benefits of eliminating legacy convertible note obligations?

The removal of over $2 million in legacy convertible note obligations is expected to materially improve the Company’s capital structure and equity profile by reducing dilution pressure.

How will BFCH communicate material updates to its shareholders?

All material updates will be published through the OTC Markets Disclosure & News Service and in compliance with applicable securities laws.